GLPwatch

Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.

NCT06856928 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing how anti-obesity medications affect appetite and related hormones in adults with obesity.

Status Not yet recruiting Approved but enrollment has not started.
Type Observational
Participants 16 people Planned (estimated).
Who can join Ages 25–60 · all sexes
Timeline Started 2025-03 · est. completion 2027-12

What this study is testing ClinicalTrials.gov NCT06856928 ↗

Description as written by the study sponsor.

This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake. Researchers will examine two groups: one just starting AOMs and another that has already achieved significant weight loss and maintained it. By conducting meal challenges at different stages of medication use, the study will assess feasibility of the methods and gather preliminary data to design a larger, future study.

Treatments tested

Main thing measuredParticipant Recruitment
SponsorUniversity of Colorado, Denver
Conditions studiedObesity; Drug
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06856928 ↗